Learn how GLP-1 medications may affect appetite and food cravings, plus what emerging research suggests about alcohol use and other addictive behaviors.
Glucagon-like peptide-1 receptor agonists, commonly called GLP-1 medications, are best known for their roles in type 2 diabetes and chronic weight management. These medications can influence appetite, fullness, digestion and blood glucose regulation.
Some patients also report changes in food preferences or fewer thoughts about food while taking treatment. Researchers are now studying whether GLP-1 medications may influence alcohol consumption and other reward-related behaviors.
The evidence is promising in some areas, but important limitations remain. GLP-1 medications are not currently approved by the U.S. Food and Drug Administration (FDA) to treat alcohol use disorder, substance use disorder, binge-eating disorder or a broadly defined “food addiction.”
GLP-1 is a naturally occurring hormone involved in appetite and blood glucose regulation. GLP-1 receptor agonists imitate some of its activity.
Depending on the medication and its approved indication, effects may include:
FDA prescribing information for semaglutide states that its effects on body weight are likely mediated through appetite regulation. GLP-1 receptors are also present in areas of the brain involved in appetite.
Tirzepatide acts on both glucose-dependent insulinotropic polypeptide and GLP-1 receptors. It is approved under specific brand names for certain metabolic and weight-related indications, not as a treatment for addictive behaviors.
Appetite, hunger and cravings are related, but they are not identical.
Hunger is the body’s physiological drive to eat.
Appetite is the desire to eat and may be influenced by hunger, environment, habits and emotions.
Cravings are more specific urges for a particular food, drink or experience.
A person can feel physically full while still wanting a particular food because of stress, habit, taste or environmental cues. GLP-1 medications may reduce appetite, but that does not mean they eliminate every emotional, behavioral or social reason a person eats.
Some people taking GLP-1-based treatment report:
These experiences are plausible because the medications affect appetite and satiety. However, responses vary and there is no reliable basis for claiming that a specific percentage of all patients will experience reduced cravings.
Statements such as “90% of people report fewer cravings” should not be presented without a clearly identified, well-designed study supporting that exact figure.
GLP-1 medications should also not be described as erasing cravings or permanently changing a person’s relationship with food.
“Food noise” is an informal term used to describe frequent or intrusive thoughts about eating.
It may include:
Some patients say these thoughts become quieter during GLP-1 treatment. This may reflect reduced appetite, earlier fullness or changes in how rewarding certain foods feel.
“Food noise” is not a formal medical diagnosis. Persistent distress around eating may require evaluation for binge-eating disorder, depression, anxiety, restrictive eating or another behavioral health concern.
GLP-1 receptors are found in brain regions involved in appetite and reward-related processing. This has led researchers to investigate whether GLP-1 medications may influence responses to highly rewarding foods, alcohol, nicotine or other substances.
Animal studies have reported effects on alcohol intake and drug-seeking behavior. These findings help researchers identify possible mechanisms, but animal results cannot establish that a medication safely or effectively treats addiction in people.
It is also too simplistic to say that GLP-1 medications merely “block dopamine spikes.” Reward-related behavior involves multiple brain regions, neurotransmitters, hormones, learned associations and environmental influences.
Emotional eating refers to eating in response to feelings such as:
Reduced appetite may make some episodes of emotional eating less likely or less intense. However, GLP-1 medications do not directly resolve the emotions, habits or circumstances driving the behavior.
A comprehensive approach may include:
Medication may support weight management, but it should not replace behavioral care when eating patterns are causing distress.
Binge-eating disorder is a recognized mental health condition involving repeated episodes of consuming unusually large amounts of food while experiencing a sense of loss of control.
Possible signs include:
GLP-1 medications are not currently FDA approved to treat binge-eating disorder.
People with suspected binge-eating disorder should receive an appropriate evaluation rather than relying only on appetite suppression. Evidence-based treatment may include psychotherapy, nutritional support and FDA-approved medication when appropriate.
Restrictive dieting and appetite suppression without behavioral support can be harmful for some people with disordered eating.
Research into GLP-1 medications and alcohol use has expanded.
A small randomized clinical trial published in 2025 evaluated once-weekly semaglutide in adults with alcohol use disorder. The findings provided early prospective evidence that low-dose semaglutide reduced alcohol craving and some drinking outcomes. The authors emphasized that larger clinical trials are needed.
Reviews of the available research have found encouraging signals but inconsistent results across medications and studies. Some trials reported reductions in drinking while others did not show a significant effect on primary alcohol-related outcomes. Larger randomized trials are needed before GLP-1 medications can be established as treatments for alcohol use disorder.
No GLP-1 medication is currently FDA approved to treat alcohol use disorder.
A person should not begin semaglutide, tirzepatide or another metabolic medication solely to manage alcohol cravings unless participating in an appropriately supervised clinical trial or receiving care for an approved indication.
FDA-approved medications for alcohol use disorder are already available. Depending on the individual, treatment may involve:
GLP-1 medications should not replace established addiction treatment.
Animal research and observational studies have explored whether GLP-1 receptor activity may affect nicotine or other drug-related behaviors.
This research remains preliminary. It does not establish GLP-1 medications as safe or effective treatments for:
Each condition has different biological, behavioral and social components and requires individualized, evidence-based care.
People should not use a GLP-1 medication off-label for addiction based on animal studies, social media reports or personal testimonials.
Food cravings may be influenced by:
A medication that reduces appetite may not address these underlying contributors.
Severe restriction can sometimes increase preoccupation with food, particularly if a person is not consuming adequate nutrition.
Prescription weight-management medication may be considered for certain adults with obesity or overweight accompanied by qualifying weight-related health conditions.
Eligibility depends on factors such as:
GLP-1 treatment is generally used alongside nutrition, physical activity and ongoing medical care rather than as a standalone solution.
GLP-1-based medications can cause side effects.
Common gastrointestinal effects may include:
Other potential concerns vary by product and may include:
Patients should review the complete prescribing information for the specific medication being considered.
A reduced appetite can support weight management, but eating too little may contribute to:
Patients should prioritize:
A provider or registered dietitian may help develop an individualized plan.
Some patients may encounter compounded versions of GLP-1-based medications.
Compounding is not the same as FDA approval. A compounded medication may be considered in limited circumstances when a licensed prescriber identifies a patient-specific need that cannot be met by an available FDA-approved product.
Compounded medications are not FDA approved and are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.
Patients should understand the exact active ingredient, source, concentration, dosing instructions and reason compounding is being considered.
Seek professional help when alcohol or substance use:
Alcohol withdrawal can be medically dangerous. People who drink heavily or experience withdrawal symptoms should not stop suddenly without medical guidance.
Emergency care is appropriate for severe confusion, hallucinations, seizures, difficulty breathing, loss of consciousness or other life-threatening symptoms.
Before beginning GLP-1 treatment, consider asking:
Patients seeking help for alcohol, binge eating or another behavioral concern should also ask whether a mental health or addiction specialist should be involved.
GLP-1 medications are established treatments for specific metabolic and weight-related conditions. By affecting appetite, fullness and digestion, they may also reduce food cravings or food-related preoccupation for some patients.
Early research suggests that GLP-1 receptor agonists may influence alcohol craving and certain drinking outcomes. However, this area remains investigational and larger clinical trials are needed.
These medications should not be described as proven treatments for alcohol use disorder, substance use disorder, food addiction, emotional eating or binge-eating disorder.
TeleWellnessMD® connects patients with licensed healthcare providers who can review medical history, weight-related concerns and treatment options to determine whether an appropriate GLP-1 therapy may be considered.
This content is for educational and informational purposes only and should not be interpreted as medical advice. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice, or dispense medications. All therapies require evaluation and approval by a licensed healthcare provider. Results may vary. Prescription required.
Learn how diet may influence GLP-1 side effects and what research shows about digestion, meal size and food choices during provider-guided care.
An overview of how 5-Amino-1MQ and lower-dose GLP-1 therapies are being discussed in wellness settings alongside lifestyle strategies that support...
Long-term chronic stress can lead to significant health consequences.
Stay informed about wellness education, patient options and affiliate opportunities with TeleWellnessMD®. Sign up to receive updates and resources by email.